medigraphic.com
ISSN 1561-2988 (Print)

2019, Number 3

<< Back

Rev Cubana Farm 2019; 52 (3)

Advantages and disadvantages of ready-to-use premixed drugs

Alviz AAA, Tarón DA, González CT

Language: Spanish
References: 33
Page: 1-17
PDF size: 445.84 Kb.


ABSTRACT

Introduction: Medication errors catch the attention of the public and entities of safety in the use of drugs, what constitutes a central element in public health policies. Premixed drugs and other systems of presentation of intravenous medications are a strategy for the pharmaceutical industry that allows reducing medication errors.
Objective: To conduct a systematic review of the literature on the advantages and disadvantages of premixed drugs.
Methods: Qualitative research from the systematic review of the scientific literature consulted at EBSCO, Sciencedirect and Medline from its search engine PubMed with the use of the search terms Premixed Drug, Premixed Drugs and Intravenous medication errors implementing the respective crosses to select the most notable articles.
Conclusion: Premixed drugs as reported in literature reduce medication errors, they are standardized and are more cost-effective; which represents efficiency and patient safety for hospitals and health institutions. Despite the productivity that exists for scientific literature at the international level, nowadays there are few studies on the premixed and their usefulness.


REFERENCES

  1. Lacasa Arregui C, Giraldez Deiró J Giráldez, Idoate García A. Administración intravenosa de medicamentos técnicos En: NAU LLIBRES, editor. Mezclas Intravenosas y Nutrición Artificial [Internet]. 4th ed. SEFH; 2000. p. 92-119. [acceso 10/12/2016] Disponible en: www.sefh.es/bibliotecavirtual/mivyna/miv04.pdf

  2. Rosselli D. Los medicamentos premezclados y su papel en la seguridad de las unidades de cuidado intensivo. Cent Gest Hosp. 1999;45(1):21-6.

  3. Vesant D, Renade Jhon B. Cannon Drug Deliver System. Third. CRC Press Taylor and Francis Group, editor. CRCnetBASE; 2011. 608 p.

  4. Rosselli D, Rueda JD, Silva MD, Salcedo J. Economic Evaluation of Four Drug Administration Systems in Intensive Care Units in Colombia. Value Heal Reg Issues SC. 2014;(40):20-4.

  5. Bates DWV, Timothy V, Diane S, Cynthia. Y, Jeffrey. R. Variability in Intravenous Medication Practices: Implications for Medication Safety. Jt Commision J Qual Patient Saf. 2005;31(4):203-10.

  6. Institute of Medicine. To Err Is Human: Building a Safer Health System [Internet]. Washington, D.C.: The National Academies Press.; 2000. Disponible en: http://doi.org/10.17226/9728

  7. Ministerio de Sanidad y Política Social de España O. Estudio IBEAS Prevalencia de efectos adversos en hospitales de Latinoamérica; 2009. p. 2-298.

  8. Ministerio de la Protección Social. Herramientas para promover la estrategia de la seguridad del paciente en el Sistema Obligatorio de Garantía de Calidad de la Atención en Salud. Bogotá D.C.; 2007.

  9. Rich DS, Jr MPF, Cohen MR, Levine SR. Original Article Guidelines for the Safe Preparation of Sterile Compounds: Results of the ISMP Sterile Preparation Compounding Safety Summit of October 2011. Hosp Pharm. 2013;48(April):282–94.

  10. Calabrese AD, Erstad BL, Barletta JF, Kane SL, Sherman DS. Medication administration errors in adult patients in the ICU. Intensive Care Med. 2001;27:1592-8.

  11. Loeb A, And DF, Kochis T. Premixed intravenous admixtures: a critical challenge for hospital pharmacy. Am J Hosp Pharm. 1983;40(6):1041-3.

  12. Schneider P. Latiolais Leadership Program Consensus Development Conference on the Safety of Intravenous Drug Delivery Systems. En: Pharmacy C of, editor. Latiolais Leadership Program Consensus Development Conference on the Safety of Intravenous Drug Delivery Systems. The Ohio State University; 1999. p 11.

  13. Bates DWV, Dugger BH, Gosbee JW, Schneider PJ, Cousins DD, Flynn E, et al. Consensus Development Conference on the Safety of Intravenous Drug Delivery Systems Consensus Statement. In: Consensus Development Conference on the Safety of Intravenous Drug Delivery Systems Consensus Statement. 1999:1-43.

  14. Patterson TR, KE Nordstrom. An analysis of intravenous additive procedures nursing units. AJHP. 1968;25:134-7.

  15. Thur MP, Miller WA, Latiolais CJ. Medication errors in a nurse-controlled parenteral admixture program89. AJHP. 1972;29(4):298-304. Revista Cubana de Farmacia. 2019;52(3):e97 Esta obra está bajo una licencia https://creativecommons.org/licenses/by-nc/4.0/deed.es_ES 16

  16. O’Hare MC, AM Bradley, T Gallagher, MD Shields. Errors in administration of intravenous. drugs Br Med J. 1995;310:1536-7.

  17. Sanders LH, SA Mabadeje, KE Avis, CA Cruze, DR Martinez. Evaluation of compounding accuracy and aseptic technique for intravenous admixtures. AJHP. 1978;35(5):531-6.

  18. Flynn EA, RE Pearson, KN Barker. Observational study of accuracy in compounding admixtures at five hospitals. Am J Heal Pharm. 1997;54(8):904-12.

  19. Kirschenbaum BE, L Cacae, RJ Anderson, LA Ackerman. Perssonel time and preparation costs for compounded versus premixed intravenous admixtures in three community hospitals. AJHP. 1988;45(3):605-8.

  20. Arnold TR, Hepler DC. Bacterial contamination of intravenous fluids in unsterile air. AJHP. 1971;28(8):614-9.

  21. Mackel DC, Maki DG, Anderson RI, Rhame FS, Bennett JV. Nationwide epidemic of septicemia caused by contaminated intravenous products: mechanisms of intrinsic contamination. J Clin Microbiol. 1975;2(6):436-97.

  22. ISMP. Sterile compounding tragedy is a symptom of a broken system on many levels. Medicat Saf Alert. 2012;17(21):1-4.

  23. McVeigh K. Meningitis outbreak: Massachusetts agencies “failed to enforce regulations.” The Guardian [Internet]. Massachusetts; 2012. [acceso 25/04/2016] Disponible en: http://m.guardian.co.uk/society/2012/oct/13/meningitisoutbreak-

  24. Miller WA, George LS, Clifton JL. A comparative evaluation of compounding costs and contamination rates of intravenous admixture systems. Drug Intell Clin Pharm. 1971;71(5):51- 60.

  25. Thur MP, William AM, Clifton JL. Medication errors in a nurse-controlled parenteral admixture program. AJHP. 1972;29(4):298-304.

  26. Alvarez C. Cifuentes Luis Fernando. El sistema cerrado en la prevención de las infecciones del torrente sanguíneo. Acta Medica Colomb. 2011;36(2):105–7

  27. Douglass K, Kastango USP ,797. Compliance survey: measuring progress. Pharm Purch Prod. 2012;8(10):S4-24.

  28. Pedersen CA, Schneider PJ SD. ASHP national survey of pharmacy practice in hospital settings: dispensing and administration – 2011. Am J Heal Syst Pharm. 2012;69:768–85.

  29. Adachi WD, Endo AY TJ. Controlling admixture waste through pharmacist monitoring. Am J Hosp Pharm. 1984;5(41):883.

  30. Vogel DP, Eck TA, Witte KW. Calculation of products waste in i.v. admixture programs. American Journal of Hospital Pharmacy. 1986;43(4):952–3.

  31. Smith CF, Amen RJ. Comparison of seven methods of preparing and administering smallvolume injections. American Journal of Hospital Pharmacy. 1988;45(9):1896–901.

  32. Lee HE. Premixed intravenous admixtures: A positive development for hospital Page 22 of 43 pharmacy. AJHP,. 1983;40(6):1043-4.

  33. IQVIA. IMS National Sales Perspectives TM. Julio 2011-Junio 2012; 2012. [acceso 11/12/2012] Disponible en: https://www.iqvia.com




2020     |     www.medigraphic.com